Pds Biotechnology Corporation · NASDAQ:PDSB
Pds Biotechnology — Investor Presentation (January 2022)
22 slides from Pds Biotechnology's investor presentation, Jan 7, 2022
Slide 1: Investor Presentation
INVESTOR PRESENTATION Frank Bedu-Addo Ph.D. President & CEO January 2022
Slide 2: Forward Looking Statements
2 This presentation contains forward-looking statements about PDS Biotechnology Corporation (“PDSB”), and its businesses, business prospects, strategies and plans, including but not limited to statements regarding anticipated pre- clinical and clinical drug development activities and timelines and m
Slide 3: Corporate Overview
Clinical-stage Company developing broad-based immunotherapies to treat cancer and infectious diseaseVersamune® and Infectimune™ platforms leverage the body’s own defense systems to prime antigen-specific killer T-cells and antibodies to combat cancer and infectious diseaseThree phase 2 oncology clin
Slide 4: Versamune Oncology Platform
Versamune® Oncology Platform
Slide 5: HPV16-associated cancers and lead asset PDS0101
5 More than 40,500 patients were estimated to have been diagnosed last year with HPV16-associated cancers in the US1, 2HPV vaccination is not expected to impact the rate of HPV-related cancer incidence for decadesExisting immunotherapies cost $150,000+ annually per patient3 1SEER Research Data 1975-
Slide 6: ASCO 2021: Triple combination shows promising durability in HPV16-positive patients
6 ASCO 2021: Triple combination shows promising durability of potential for anti-cancer efficacy in HPV16-positive patients PDS0101 + Bintrafusp alfa + M9241 Standard of Care(Checkpoint Inhibitors) HPV16-positive Number of checkpoint inhibitor naïve patients 6 Survival at median of 8 months 100% (6/
Slide 7: ASCO 2021 interim proof-of-concept data: tumor shrinkage
ASCO 2021 Interim proof-of-concept data suggests targeted CD8+ killer T-cell response induced by Versamune® results in tumor shrinkage 7 Reference: Strauss J. et al. Phase II evaluation of the triple combination of PDS0101, M9241, and Bintrafusp alfa in patients with HPV 16 positive malignancies. Pr
Slide 8: Versamune is designed to Recruit, Train and Arm T-cells
Versamune® is designed to Recruit, Train and Arm T-cells in the body 8 References: Gandhapudi SK, et al. 2019. Antigen priming with enantiospecific cationic lipid nanoparticles induces potent antitumor CTL responses through novel induction of a Type I IFN response. J Immunol. 202 (12): 3524-3536. Sm
Slide 9: Versamune promotes powerful CD8+ killer T-cell responses
9 Generate the right type and quantity of effective CD8+ killer T-cells Generate potency without serious systemic side effects Generate memory T-cells, to enhance durability of response Competitve Barrier to Entry:Versamune® is designed to promote powerful, CD8+ killer T-cell responses in vivo Versa
Slide 10: Strong Pipeline with Industry Leading Partnerships
Strong Pipeline with Industry Leading PartnershipsVersamune® -based oncology pipeline is being developed in partnership with the leaders in immuno-oncology 10 Reference: Data on file.
Slide 11: Phase 2: PDS0101 + KEYTRUDA
11 Phase 2: PDS0101 + KEYTRUDA®Company-sponsored trial for the treatment of HPV16-positive metastatic/recurrent head and neck cancer (VERSATILE-002) Indication Treatment of patients with HPV16-positive head and neck cancer whose cancer has spread or returned Clinical Agents KEYTRUDA® (Standard of Ca
Slide 12: Phase 2: PDS0101 + Chemoradiotherapy
12 Phase 2: PDS0101 + ChemoradiotherapyInvestigator-led trial evaluating the combination in patients with locally advanced cervical cancer (IMMUNOCERV) Indication Treatment of patients with locally advanced cervical cancer – Stages IB3-IVA Clinical Agents Chemoradiotherapy (CRT – Standard of Care):
Slide 13: PDS0102: TARP antigen
13 13 PDS0102: TARP antigen Greater quantity and quality of Versamune®-induced CD8+ killer T-cells may result in ability to treat TARP positive prostate and breast cancers 1 Reference: Wood LV et al, Oncoimmunology, 2016, Vol. 5 (8)CFA – Complete Freund’s Adjuvant a highly potent immune activator no
Slide 14: PDS0103: MUC1 antigen
14 14 PDS0103: MUC1 antigenGreater quantity and quality of Versamune®-induced CD8+ killer T-cells may result in ability to treat MUC1-positive cancers Induced a >10-fold number of polyfunctional (highly potent) MUC1 specific CD8+ T-cells Adjuvant = cytokine GMCSFReferences: J. Immunology, 2019 (202)
Slide 15: Infectimune Infectious Disease Platform
Infectimune™Infectious Diseased Platform
Slide 16: Infectimune Pipeline
PDS Biotech’s Infectimune™ Pipeline Developed in partnership with leaders in infectious disease 16 Reference: Data on file. *Consortium of PDS Biotech, Farmacore Biotechnology and Blanver Farmoquimica. Funding provided by The Ministry of Science, Technology and Innovation of Brazil (“MCTI”)
Slide 17: Infectimune Pipeline Update on Infectious Disease
Universal Flu Announced Option Agreement for license with University of Georgia for universal flu antigens Preclinical work completeCOVIDAgreement with Farmacore extended through May 2022Scale up and manufacturing currently in process Infectimune™ Pipeline Update on Infectious Disease 17
Slide 18: Near-Term Milestones
Near-Term Milestones
Slide 19: Projected milestones through 2022
Projected milestones through 2022* *Based on current enrollment and forecast modeling as of January 2022. Subject to change. 4Q22 3Q22 2Q22 1Q22 4Q21 3Q21 2Q21 Preliminary efficacy data from advanced HPV-associated cancer trial (NCI) Interim data from HPV-associated cancer trial (NCI) Preliminary da
Slide 20: PDS Biotech Management
PDS Biotech ManagementHistorical success in the development and commercialization of leading pharmaceutical products 20 Senior executive experience with management of strategy and execution at both large pharma and biotechsNotable drug development:Abelcet® (Liposome Company/ Elan)PEG-Intron® (Scheri
Slide 21: Corporate Overview
Clinical-stage Company developing broad-based immunotherapies to treat cancer and infectious diseaseVersamune® and Infectimune™ platforms leverage the body’s own defense systems to prime antigen-specific killer T-cells and antibodies to combat cancer and infectious diseaseThree phase 2 oncology clin
Slide 22: PDS Biotechnology Precision Designed Science to Treat Cancer
PDS Biotechnology Nasdaq: PDSB Precision Designed Science to Treat Cancer
PDS Biotechnology — Investor Presentation (January 2022) on 6ix